Nabilone for Agitation in Frontotemporal Dementia

NCT05742698

Status	RECRUITING
Phase	Phase 2
Sponsor	Simon Ducharme, MD
Enrollment	45 participants

Key Eligibility Criteria

Inclusion (7)

- Men and women over 18 years
- Major neurocognitive disorder due to probable behavioural variant FTD (Rascovsky criteria)17 or primary progressive aphasia (Gorno-Tempini criteria)18. All ages and severity levels will be included.
- Meets International Psychogeriatric Association criteria for agitation in cognitive disorders19
- CMAI score of 39 or above
- Stable psychoactive medication for 2 weeks prior to screening (all medications allowed) with no intention to change dose during treatment period

... and 2 more (see full listing online)

Exclusion (11)

- Clinically significant psychotic symptoms (Neuropsychiatric Inventory domain score (severity x frequency) e4 on the delusions or hallucinations subscale)
- Clinically significant orthostatic hypotension (a decrease in systolic blood pressure of 20 mm Hg or in diastolic blood pressure of 10 mm Hg within three minutes of standing compared to blood pressure in a seated position)
- Symptomatic orthostatic tachycardia (heart rate increase from of at least 30 beats per minute within the first 5 minutes of standing compared to a seated position IF orthostatic hypotension is not a problem)
- Unstable cardiovascular condition in the opinion of the investigator
- Known or suspected history of drug or alcohol dependence or abuse in the past 12 months, including use of any psychomimetic drugs (e.g. ketamine, lysergic acid diethylamide, psilocybin).

... and 6 more (see full listing online)

Locations (7 total)

University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada
Brain and Mind Institute, University of Western Ontario, London, Ontario, Canada
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
... and 4 more locations